CAR T-cell Therapy for NHL Clinical Trial Landscape Expands: Over 70 Companies Advancing Next-Generation Therapies | DelveInsight

New York, USA, Sept. 10, 2026 (GLOBE NEWSWIRE) -- CAR T-cell Therapy for NHL Clinical Trial Landscape Expands: Over 70 Companies Advancing Next-Generation Therapies | DelveInsight

The CAR T-cell therapy for NHL clinical trial analysis report delivers important insights into ongoing research of 75+ pipeline CAR T-cell therapies for NHL, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'CAR T-cell Therapy for NHL Pipeline Insight 2026' report provides comprehensive global coverage of pipeline CAR T-cell therapy for NHL across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the CAR T-cell therapy for NHL domain.

CAR T-cell Therapy for NHL Clinical Trial Analysis Summary

• DelveInsight’s CAR T-cell therapy for NHL pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline CAR T-cell therapies for NHL. 
• Key CAR T-cell therapy for NHL companies, such as Lyell Immunopharma, Inc., Kure Cells, Inc., Allogene Therapeutics, Elicera Therapeutics, Caribou Biosciences, CARsgen Therapeutics, Marker Therapeutics, Inc., Orcar Bio, Imugene Limited, Cellectis, Luminary Therapeutics, Allotera Therapeutics, Prescient Therapeutics, March Biosciences, Legend Biotech, Miltenyi Biomedicine, Imviva Biotech, AvenCell Therapeutics, Umoja Biopharma, AbelZeta Pharma, Inc., Leman Biotech Co., Ltd., and others, are evaluating new CAR T-cell therapies for NHL to improve the treatment landscape.
• Promising pipeline CAR T-cell therapies for NHL, such as Rondecabtagene autoleucel, UF-KURE19, Cemacabtagene Ansegedleucel, ELC-301, Vispa-cel, CT1190B, MT-601, Research Program: NHL, Azer-cel, Eti-cel, LMY-920, Sofi-cel, PTX-100, MB-105, MB-107, LB2501, LB2302, Zamto­cabta­gene autoleucel, CTD402, AVC-203, UB-VV400/410, UB-VV300/310, Prizloncabtagene Autoleucel, META 10-19, and others, are in different phases of CAR T-cell therapy for NHL clinical trials.
• Approximately 15+ CAR T-cell therapies for NHL are in the late and mid stages of development.
• Notable target types in CAR T-cell therapy for NHL clinical trials include CD19, CD20, Survivin, PRAME, WT-1, NY-ESO-1, SSX-2, MAGEA-4, and others.

Request a sample and discover the recent advances in CAR T-cell therapy for NHL treatment @ https://www.delveinsight.com/report-store/car-t-cell-therapy-for-non-hodgkins-lymphoma-pipeline-insight

What is CAR T-cell Therapy for NHL?

CAR T-cell therapy is an advanced form of immunotherapy used to treat certain types of non-Hodgkin lymphoma (NHL), particularly aggressive B-cell lymphomas that have relapsed or become resistant to standard treatments. The therapy involves collecting a patient’s own T cells from the blood and genetically modifying them in a laboratory to express a chimeric antigen receptor (CAR) that recognizes specific proteins, such as CD19, on lymphoma cells. The modified T cells are then expanded and infused back into the patient, where they can identify and attack cancer cells. CAR T-cell therapy has transformed the treatment landscape for relapsed or refractory NHL by providing durable responses in some patients who have limited treatment options. However, the therapy can be associated with potentially serious adverse effects, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), requiring specialized monitoring and management.

Find out more about treatment for CAR T-cell therapy for NHL @ CAR T-cell Therapy for NHL New Treatment

A snapshot of the Pipeline CAR T-cell Therapy for NHL Drugs mentioned in the report:

Learn more about the CAR T-cell therapy for NHL research @ CAR T-cell Therapy for NHL Clinical Trials 

Stuti Mahajan, consulting manager at DelveInsight, said that the NHL CAR-T market is entering a new wave of innovation, with a rapidly expanding pipeline seeking to overcome limitations of current CD19-directed therapies through dual-targeting, allogeneic, and in-vivo approaches. Growing clinical activity across earlier treatment lines and hard-to-treat relapsed/refractory populations is broadening the potential addressable patient pool, while continued trial initiations and regulatory milestones are sustaining competitive momentum.

Recent Developments in CAR T-cell Therapy for NHL Treatment Space

• In August 2026, AbelZeta Pharma, Inc. announced that the Company received the US Food and Drug Administration (FDA) clearance of IND application for C-CAR039, also known as Prizloncabtagene Autoleucel (Prizlon-cel), an anti-CD20/CD19 bispecific CAR-T, for the treatment of relapsed or refractory (r/r) Large B-cell Lymphoma (LBCL).
• In July 2026, Allogene Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to cemacabtagene ansegedleucel (cema-cel) for the treatment of adult patients with large B-cell lymphoma (LBCL) who, at the completion of first-line (1L) therapy, are in complete or partial response suitable for observation but test positive for minimal residual disease (MRD).
• In July 2026, Umoja Biopharma announced that the FDA has cleared its Investigational New Drug (IND) application for UB-VV400, a CD22-directed in vivo CAR T-cell therapy candidate for adults with relapsed or refractory B-cell malignancies. 
• In June 2026, Caribou Biosciences, Inc. announced that vispa-cel, its off-the-shelf CD19-targeted CAR-T cell therapy, produced durable long-term responses in patients enrolled in the ANTLER Phase I clinical trial for relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL), with the potential to bring the benefit of cell therapy to patients who lack curative options.
• In June 2026, Lyell Immunopharma, Inc. announced new safety data from the ongoing Phase I/II clinical trial of rondecabtagene autoleucel (ronde-cel) in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third- and later-line (3L+) settings and new translational data for ronde-cel.
• In June 2026, Legend Biotech Corporation reported the first clinical proof-of-concept results for LB2501, its investigational in vivo dual-targeting CD19/CD20 CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The findings are being showcased in a late-breaking presentation (Abstract #LB5006) at the 2026 European Hematology Association (EHA) Congress.
• In May 2026, CARsgen Therapeutics Holdings Limited announced that the Investigational New Drug (IND) application for CT1190B (an allogeneic CAR T-cell product targeting CD19/CD20) was accepted by the National Medical Products Administration (NMPA). The product is intended to be used for the conduct of a Phase Ib clinical trial in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least two lines of prior standard therapy. 
• In May 2026, Miltenyi Biomedicine has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for zamtocabtagene autoleucel (zamto cel) for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBL), primary mediastinal large B-cell lymphoma (PMBCL) and transformations of indolent B-cell lymphomas who relapsed within 24 months from start of, or are refractory to, first-line chemoimmunotherapy. 
• In March 2026, Leman Biotech Co., Ltd. announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for META 10-19, a metabolically armored CD19-targeted CAR-T cell therapy. The IND clearance enables the initiation of US-based clinical studies for patients with relapsed or refractory (R/R) CD19-positive B-cell hematologic malignancies. Targeted indications include B-cell non-Hodgkin lymphoma (B-NHL), such as diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).
• In February 2026, Lyell Immunopharma, Inc. announced that the first patient has been dosed in the PiNACLE – H2H Phase III trial evaluating rondecabtagene autoleucel (ronde-cel, also known as LYL314) compared to lisocabtagene maraleucel (liso-cel) or axicabtagene ciloleucel (axi-cel) for the treatment of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) receiving treatment in the second-line (2L) setting.

Scope of the CAR T-cell Therapy for NHL Pipeline Report 

• Coverage: Global 
• CAR T-cell Therapy for NHL Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• CAR T-cell Therapy for NHL Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• CAR T-cell Therapy for NHL Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Key CAR T-cell Therapy for NHL Companies: Lyell Immunopharma, Inc., Kure Cells, Inc., Allogene Therapeutics, Elicera Therapeutics, Caribou Biosciences, CARsgen Therapeutics, Marker Therapeutics, Inc., Orcar Bio, Imugene Limited, Cellectis, Luminary Therapeutics, Allotera Therapeutics, Prescient Therapeutics, March Biosciences, Legend Biotech, Miltenyi Biomedicine, Imviva Biotech, AvenCell Therapeutics, Umoja Biopharma, AbelZeta Pharma, Inc., Leman Biotech Co., Ltd. and others.
• Key CAR T-cell Therapies for NHL in Pipeline: Rondecabtagene autoleucel, UF-KURE19, Cemacabtagene Ansegedleucel, ELC-301, Vispa-cel, CT1190B, MT-601, Research Program: NHL, Azer-cel, Eti-cel, LMY-920, Sofi-cel, PTX-100, MB-105, MB-107, LB2501, LB2302, Zamto­cabta­gene autoleucel, CTD402, AVC-203, UB-VV400/410, UB-VV300/310, Prizloncabtagene Autoleucel, META 10-19  and others.

Dive deep into rich insights for CAR T-cell therapy for NHL cure; visit @ CAR T-cell Therapy for NHL News

Table of Contents

For further information on the CAR T-cell therapy for NHL clinical trials, reach out @ CAR T-cell Therapy for NHL Medication

Related Reports

CAR T-cell Therapy for NHL Market

CAR T-cell Therapy for NHL Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for NHL companies, including Miltenyi Biomedicine, Novartis, Wugen, Allogene Therapeutics, Imugene, Legend Biotech, Caribou Biosciences, Juno Therapeutics, Mustang Bio, CRISPR Therapeutics, 2seventy bio, and others.

CAR T-Cell Therapy Market

CAR T-Cell Therapy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy companies, including CytoAgents, Genentech, Incyte Corporation, Caribou Biosciences, Chimeric Therapeutics, Allogene Therapeutics, Kyverna Therapeutics, iCell Gene Therapeutics, Synthekine, Janssen Research & Development, SecuraBio, ImmPACT Bio, A2 Biotherapeutics, Gracell Biopharmaceuticals, Wugen, Sana Biotechnology, Oncternal Therapeutics, Vor Biopharma, CARsgen Therapeutics, Autolus Limited, Arcellx, Kite, Novartis, Lyell Immunopharma, ImmPACT Bio, Tmunity Therapeutics, Poseida Therapeutics, Precigen, AffyImmune Therapeutics, 2seventy bio, Takeda, Cartesian Therapeutics, Cabaletta Bio, Legend Biotech, Miltenyi Biomedicine, Beam Therapeutics, and others.

CAR-T Market

CAR-T Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR-T companies, including Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics,Shanghai Unicar-Therapy Bio-medicine Technology, Sinobioway Cell Therapy, Tessa Therapeutics, Wuhan Bio-Raid Biotechnology, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Cellular Biomedicine Group, Chongqing Precision Biotech, Eureka Therapeutics, Formula Pharmaceuticals, Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology, Mustang Bio, MolMed, Aurora BioPharma, Atara Biotherapeutics, Autolus, Bellicum Pharmaceuticals, Kecellitics Biotech Company, Yake Biotechnology, Minerva Biotechnologies, Allogene Therapeutics, PersonGen BioTherapeutics (Suzhou), Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Shanghai GeneChem, Shanghai Longyao Biotechnology, Shenzhen BinDeBio, and others.

Non-Hodgkin’s Lymphoma Market

Non-Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-Hodgkin’s lymphoma companies, including Soligenix, Innate Pharma, Nurix Therapeutics, AstraZeneca, Merck, Prescient Therapeutics, Kite Pharma, Seagen, Takeda, Novartis, Daiichi Sankyo, Genmab, AbbVie, Genentech (a Member of Roche), Bristol Myers Squibb, and others.

Non-Hodgkin’s Lymphoma Clinical Trial Analysis

Non-Hodgkin’s Lymphoma Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NHL companies, including Bristol-Myers Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679